Boehringer Ingelheim invest 55 million eur in China

30 May 2012 - Taizhou, China, and Ingelheim, Germany  Today the research based pharmaceutical company Boehringer Ingelheim and Taizhou China Medical City in Jiangsu Province, China, announced the signing of an agreement for the establishment of a veterinary vaccine manufacturing plant. Under the terms of the agreement, the plant will be built in Taizhou China Medical City, a national pharmaceutical high-tech industry park (250 kms North of Shanghai). The total investment will be more than 55.5 million euro.

Merck Serono Research Hub Beijing

 
October 2011- Merck Serono newest R&D hub established in November 2009 in the Beijing area, expanded in 2011 through a strategic partnership with Pharmaron, opening an R&D laboratory on the Pharmaron campus.

The Beijing hub leads drug development for local clinical trials and participation in global clinical trials. Merck Serono's presence enables to liaise more effectively with regulatory officials, academic institutions and other research-oriented organizations as well as conduct clinical trials that accelerate the development of products to treat high-prevalence diseases in China. There is a continuous effort to look for partnerships with local academic institutions and companies.

Research activities at the Beijing R&D hub focus mainly on biomarker research, including pharmacogenomics and bioanalytics, which is part of our stratified medicine approach. The development of Merck serono's activities are centered on Oncology, Neurodegenerative Diseases and Rheumatology. The expertise is concentrated in clinical monitoring, clinical trial management, data management, biostatistics, statistical programming, clinical development units, regulatory affairs, non-clinical development, portfolio and project management, quality assurance, drug safety and medical affairs.

Merck Serono (Beijing) Pharmaceutical R&D Co., Ltd.
The R&D Beijing Hub is an integrated R&D facility, aimed at stimulating innovation, introducing new products to Asia paralleling market timelines in the West, and leading research and development into new treatment solutions for critical diseases in Asia.

CONTACT
Merck Serono (Beijing) Pharmaceutical R&D Co., Ltd.
10F, Tower B, Gemdal Plaza,
No.91 Jianguo Road,
Chaoyang District,
100022 Beijing,
P.R. China

BioWin signs an agreement with Juke Biotech Park (Shanghai)

October 2011-

BioWin, the Health competitiveness cluster of Wallonia (Belgium), has announced that a partnership agreement was signed on the 14th of October of this year with Juke Biotech Park, a new public funded Science Park in Shanghai (China) that hosts more than a hundred Chinese SMEs and research centres specialised in health biotechnologies and medical technologies. Under the agreement, an operational infrastructure and facilities will be provided to Laurent Le Guyader, BioWin’s permanent representative in Shanghai as International Relations Manager – China. Mr Le Guyader reports to Yve van Thorenburg, International Relations Manager – Asia and Frédéric Druck, who heads the BioWin international unit. Juke Biotech Park has further undertaken to smooth the way for access to the Chinese market to BioWin members. And vice versa, BioWin will ease as much as possible the access of Juke Biotech Park companies to Wallonia as strategic gate to the European market. This agreement is the fruit of a strategy to develop the BioWin activities in China, first launched in 2009. It was signed in the course of a recent BioWin and AWEX (Walloon Export and Foreign Investment Agency) mission to the Bio China trade fair 2011. BioWin was eager to conclude this agreement to keep step with the growing interest for the Chinese market expressed by Walloon SMEs and research centres working in the field of health biotechnologies and medical technologies. This is the second agreement concluded with a preferred partner on location in Shanghai, the Chinese city that has become an indispensable hub when it comes to healthcare innovation. *** Press contacts: Frédéric Druck – BioWin Head of Communication and International Relations Tel. +32 (0)474/52.02.69 - frederic.druck@biowin.org

Novartis invest 1 billion in China

June 2011 Novartis to invest $1 billion in China Swiss pharmaceutical giant Novartis will invest $1 billion (SFr1.02 billion) research and development investment in China. The investment will include a significant expansion of the Novartis Institute of BioMedical Research (NIBR) in Shanghai. Demand for healthcare in China is growing rapidly, Novartis said in a statement. "In addition, the burden of disease now includes more chronic diseases associated with lifestyle choices," it added. "We are confident that our expanded investment in R&D will result in innovative therapies for patients in China and other countries nurtured by the growing scientific excellence in China," Novartis CEO Daniel Vasella said. The Shanghai institute will become the third largest R&D centre for Novartis, after its Cambridge, Massachusetts centre and the facility at the group's headquarters in Basel. Estimates are that the number of R&D associate positions will increase from 160 in 2009 to about 1,000.

GSK R&D invest $100 million in Shanghai, China

May 2011 - GlaxoSmithKline GlaxoSmithKline’s China R&D center has followed a steady but slow growth. In 2007, GSK announced the establishment of a USD 40 million Shanghai R&D center which, among other functions, would serve as the company’s primary center focusing on neurodegenerative disorders.

As of 2008, the company had increased its staff from 170 to 200 and stated its intention to double this number by the end of this year, as well as pursue drug discovery efforts in addition to pre-clinical and clinical trial support.

 In December 2007, GSK said it expected to have invested $100 million in its Shanghai facility by the end of 2008 and have 1.000 staff members employed there by 2010.

When it was started, GSK’ Shanghai R&D center had the stated goal of focusing on neurodegenerative diseases such as multiple sclerosis, Parkinson’s disease, and Alzheimer’s disease. The Shanghai center was tasked with eventually directing GSK’s R&D activities in this therapeutic area, coordinating with other GSK centers around the world and research institutions in China and globally.

The Shanghai center began operations in the summer of 2007.

GSK Shanghai China Building 3, 898 Halei Rd,
Zhangjiang Hi-Tech Park,
Pudong,
Shanghai, China

Bayer Pharma AG invest 100 Million EUR in Beijing, China

February 2009 

 Bayer Pharma to Invest 100 Million Euro in China to Build a Global R&D Center Bayer  Pharma AG, the pharmaceutical division of Bayer HealthCare (BHC), announced in February 2009 that it will be strengthening its global Research and Development (R&D) capabilities through the foundation of a global R&D center in Beijing, China. The company will invest some 100 million Euro over the next five years to establish the center. With the establishment of the R&D center in China, especially Asian patients will benefit from considering their clinical profile and medical needs early-on.